DA Davidson Weighs in on Prestige Consumer Healthcare Inc.’s Q2 2025 Earnings (NYSE:PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH) – DA Davidson issued their Q2 2025 earnings estimates for Prestige Consumer Healthcare in a research report issued to clients and investors on Monday, August 12th. DA Davidson analyst L. Weiser expects that the company will earn $1.08 per share for the quarter. DA Davidson has a “Buy” rating and a $93.00 price target on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.41 per share.

PBH has been the topic of several other research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. StockNews.com lowered shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $98.25.

Prestige Consumer Healthcare Price Performance

PBH opened at $68.69 on Wednesday. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of 16.47, a price-to-earnings-growth ratio of 1.88 and a beta of 0.49. Prestige Consumer Healthcare has a fifty-two week low of $56.34 and a fifty-two week high of $75.31. The company’s 50-day moving average price is $68.42 and its 200 day moving average price is $68.65. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.04. The firm had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.06 earnings per share.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the company. Congress Asset Management Co. MA increased its stake in shares of Prestige Consumer Healthcare by 596.2% during the fourth quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock valued at $41,584,000 after acquiring an additional 581,685 shares during the period. Norges Bank acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $27,739,000. Ariel Investments LLC increased its stake in shares of Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after acquiring an additional 274,212 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Prestige Consumer Healthcare by 26.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock valued at $90,891,000 after acquiring an additional 272,773 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of Prestige Consumer Healthcare by 9.0% during the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after acquiring an additional 171,357 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.